Your browser doesn't support javascript.
loading
Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Kurozumi, Sasagu; Alsaleem, Mansour; Monteiro, Cíntia J; Bhardwaj, Kartikeya; Joosten, Stacey E P; Fujii, Takaaki; Shirabe, Ken; Green, Andrew R; Ellis, Ian O; Rakha, Emad A; Mongan, Nigel P; Heery, David M; Zwart, Wilbert; Oesterreich, Steffi; Johnston, Simon J.
Afiliação
  • Kurozumi S; Nottingham Breast Cancer Research Centre, Nottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham, UK.
  • Alsaleem M; Department of General Surgical Science, Gunma University Graduate School of Medicine, Gunma, Japan.
  • Monteiro CJ; Department of Breast Surgery, International University of Health and Welfare, Narita, Japan.
  • Bhardwaj K; Nottingham Breast Cancer Research Centre, Nottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham, UK.
  • Joosten SEP; School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK.
  • Fujii T; Nottingham Breast Cancer Research Centre, Nottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham, UK.
  • Shirabe K; Gene Regulation and RNA Biology Laboratory, School of Pharmacy, University of Nottingham, Nottingham, UK.
  • Green AR; Nottingham Breast Cancer Research Centre, Nottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham, UK.
  • Ellis IO; Gene Regulation and RNA Biology Laboratory, School of Pharmacy, University of Nottingham, Nottingham, UK.
  • Rakha EA; Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Mongan NP; Department of General Surgical Science, Gunma University Graduate School of Medicine, Gunma, Japan.
  • Heery DM; Department of General Surgical Science, Gunma University Graduate School of Medicine, Gunma, Japan.
  • Zwart W; Nottingham Breast Cancer Research Centre, Nottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham, UK.
  • Oesterreich S; Nottingham Breast Cancer Research Centre, Nottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham, UK.
  • Johnston SJ; Nottingham Breast Cancer Research Centre, Nottingham Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham, UK.
Breast Cancer Res ; 22(1): 85, 2020 08 11.
Article em En | MEDLINE | ID: mdl-32782013
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Biomarcadores Tumorais / Carcinoma Lobular / Carcinoma Ductal de Mama / Receptor ErbB-2 / Mutação Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Biomarcadores Tumorais / Carcinoma Lobular / Carcinoma Ductal de Mama / Receptor ErbB-2 / Mutação Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido País de publicação: Reino Unido